Opiate Addiction Recovery in Dual Diagnosis Rehab – Katie’s Story
Opiate Addiction Recovery in Dual Diagnosis Rehab – Katie’s Story – www.sovcal.com A chronic pain patient shares her story of recovery from opiate addiction and learning to deal with chronic pain and associated problems at a Treatment Center leading in dual diagnosis treatment. She also talks about her previous unsuccessful attempts at trying to deal with her pain and how she suffered for 10 years – undergoing surgery, seeking different treatments, taking opiates with no relief, till she found a dual diagnosis treatment center that addressed chronic pain and she got herself admitted. She goes on to talk about her experience at the center, some techniques learned to deal with her problems, the progress made and how she feels that she is finally on the road to recovery. For more information about Sovereign Health of California, or if you need assistance, please call our toll free number at 866.819.2948.
New heart procedure avoids open-heart surgery
Filed under: free drug treatment centers
Patients unable to tolerate such an invasive procedure had little, if any, options until the Food and Drug Administration's approval of the transcatheter aortic heart valve, a device that requires only a small cut in the skin. The device is then …
Read more on NorthJersey.com
CULTURE DIGEST: Catholics, 4 denominations reach baptism agreement
Filed under: free drug treatment centers
Panel co-organizer Bruce Knotts, director of the Unitarian Universalist United Nations Office, expressed hope the conversation would be the first of many official discussions on the controversial treatment, the Huffington Post reported. Joining Knotts …
Read more on BP News
FDA relaxes Alzheimer's drug development guidelines
Filed under: free drug treatment centers
This "can make it difficult to determine if a given treatment's effect is clinically important". Russell Katz, director of the division of neurology products in the agency's Center for Drug Evaluation and Research, said that "the scientific community …
Read more on PharmaTimes